BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21406409)

  • 21. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venous thromboembolism in the medically ill patient: a call to action.
    Bergmann JF; Kher A
    Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
    Brouwers JRBJ; Roeters van Lennep JE; Beinema MJ
    Br J Clin Pharmacol; 2019 Nov; 85(11):2479-2486. PubMed ID: 31378961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
    Harenberg J; Kalodiki E; Walenga JM;
    Int Angiol; 2012 Apr; 31(2):101-4. PubMed ID: 22466973
    [No Abstract]   [Full Text] [Related]  

  • 26. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
    Davidson BL
    Semin Thromb Hemost; 1999; 25 Suppl 3():107-12. PubMed ID: 10549725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of deep vein thrombosis using low-molecular-weight heparins.
    Groce JB
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic forms of low-molecular-weight heparins: some practical considerations.
    Leong W; Hoppensteadt DA
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comments about dosing of low molecular weight heparins (LMWH)].
    Udvardy M; Rák K
    Orv Hetil; 2001 Sep; 142(38):2077-82. PubMed ID: 11697064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins.
    Hirsh J
    Curr Opin Hematol; 1998 Sep; 5(5):360-5. PubMed ID: 9776217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Low molecular weight heparin].
    Pini M
    Recenti Prog Med; 1997 Dec; 88(12):594-602. PubMed ID: 9522605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
    Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: are they really better?
    Huo MH
    Thromb Haemost; 2011 Jul; 106(1):45-57. PubMed ID: 21544312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs).
    Kalodiki E; Leong W;
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):8-11. PubMed ID: 19117962
    [No Abstract]   [Full Text] [Related]  

  • 40. Low-molecular-weight heparin in oncology.
    Zacharski LR; Loynes JT
    Anticancer Res; 2003; 23(3C):2789-93. PubMed ID: 12926114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.